Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) VP Jaye Thompson purchased 1,000 shares of the company's stock in a transaction on Thursday, November 21st. The shares were purchased at an average cost of $12.91 per share, with a total value of $12,910.00. Following the transaction, the vice president now directly owns 264,148 shares in the company, valued at $3,410,150.68. This trade represents a 0.38 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink.
Greenwich LifeSciences Stock Performance
Shares of GLSI stock opened at $13.94 on Tuesday. Greenwich LifeSciences, Inc. has a fifty-two week low of $8.00 and a fifty-two week high of $21.44. The firm has a market cap of $183.31 million, a P/E ratio of -17.42 and a beta of 1.62. The business's 50 day moving average price is $13.80 and its 200-day moving average price is $14.43.
Institutional Trading of Greenwich LifeSciences
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Garden State Investment Advisory Services LLC purchased a new position in Greenwich LifeSciences during the 3rd quarter valued at $253,000. Bank of New York Mellon Corp bought a new stake in shares of Greenwich LifeSciences during the 2nd quarter valued at about $264,000. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences during the second quarter valued at about $117,000. Barclays PLC raised its stake in Greenwich LifeSciences by 323.3% in the third quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after buying an additional 6,538 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Greenwich LifeSciences by 4.6% in the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock worth $1,919,000 after buying an additional 5,861 shares during the period. Hedge funds and other institutional investors own 4.16% of the company's stock.
Analyst Ratings Changes
What Are Buffett, Dalio, and Druckenmiller So Worried About?
From Stansberry Research | Ad
"This Will Be Worse Than The Great Depression, The Dot-Com Crash, And The 2008 Crisis Combined"
According to Dan Ferris, who has predicted nearly every major market crisis of the last 25 years, a new crisis in the US economy could soon cost you 50% of your portfolio or more if you don't prepare your wealth now. Especially if you’re sitting on large gains.
Click here to see the new crisis that could abruptly end this current bull market.
Separately, HC Wainwright increased their target price on shares of Greenwich LifeSciences from $36.00 to $38.00 and gave the stock a "buy" rating in a report on Friday, August 23rd.
View Our Latest Analysis on GLSI
About Greenwich LifeSciences
(
Get Free Report)
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
